ClinicalTrials.gg
Active, not recruitingNCT02307630Updated Dec 4, 2025

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

An interventional study of 124I-Humanized 3F8 in Melanoma, Neuroblastoma and Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 3 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
3 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies in Melanoma by Memorial Sloan Kettering Cancer Center — 6 open to participants now, 19 under way, 2 of them phase 3. Melanoma · Memorial Sloan Kettering Cancer Center.

Enrollment
37th of 43
7 · median 24
Started
2014
with 1 other
No phase
6 of 67
1 open now
Primary completion
2026-11
later than 0 of 18 live
Registered
48th of 67
by date

Among the 67 studies in Melanoma by Memorial Sloan Kettering Cancer Center, this one is the 37th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 with no phase, reaches primary completion later than 0 of the 18 other live ones, and was the 48th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 67 studies in Melanoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 3 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Melanoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodies can be made by your own body or in a laboratory. The target of an antibody is called an antigen; antibodies fit their antigen like a lock fits a key.

03

Conditions studied

  • Melanoma
  • Neuroblastoma
  • Sarcoma

Keywords

  • 124I-Humanized 3F8
  • PET Imaging
  • 13-147
04

Who can participate

Ages eligible
3 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with the diagnosis of neuroblastoma must meet both of the following criteria:

    • Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM PLUS elevated urinary catecholamines
    • stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease.
    • Patients with tumors other than neuroblastoma must meet both the following criteria:
    • Have one of the following diagnoses (these tumors are known to express GD2 on cell surface):
    • Melanoma
    • Osteogenic sarcoma
    • Leiomyosarcoma
    • Ewing sarcoma
    • Liposarcoma
    • Fibrosarcoma
    • Malignant fibrous histiocytoma
    • Spindle cell sarcoma
    • Small cell lung cancer
    • Medulloblastoma metastatic to extracranial sites
    • Paraganglioma
    • Have refractory or relapsed or metastatic disease
    • Patients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria:
    • Immunohistochemical demonstration of GD2 expression on cell surface (Tumor assessment by immunohistochemistry is required for this group of patients)
    • Have refractory or relapsed disease or metastatic disease. All patients must have measurable or evaluable disease
    • Age 3-90 years
    • Prior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is ≤1300 assay developed by Dr. Nai-Kong Cheung.
    • Negative serum pregnancy test in women of
    • Women of child-bearing potential must be willing to practice an effective method of while on study
    • Signed indicating awareness of the nature of this study.

Exclusion criteria

Exclusion Criteria:

  • Existing major organ dysfunction > grade 2, with the exception of myelosuppression ( > or = 500/μl and count > or = 25,000/μl are acceptable) and hearing loss.

    • Acute life threatening infection
    • Requirement for sedation for PET/CT scans
    • Pregnant women or women who are breast-feeding.
    • Inability to comply with protocol requirements.
    • to potassium iodide or Lugols products
    • Prior development of positive human antimouse antibody response (HAMA) or human antihuman antibody response (HAHA)
    • Positive human anti-hu3F8 antibody titer.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    PET Imaging using 124I-Humanized 3F8

    124I-hu3F8 at a dose of 3mCi/m2 (with a maximum dose of 5mCi) will be injected IV. 124I-hu3F8 PET/CT scans will be performed at approximately 2-4 hours, 18-26hours, 48-72 hours and 96-144 hours after injection of 124I-hu3F8. A low dose CT scan will be obtained with each PET scans. PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8 and to determine dosimetry to organs and sites of disease. Comparison of tumor targeting and tumor dosimetry will be made between the two cohorts of patients: (a) NB and (b) other solid tumors. Blood will be drawn where feasible at multiple time points: approximately 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120h-144h after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.

    Biological: 124I-Humanized 3F8

Interventions

  • Biological124I-Humanized 3F8
06

What researchers measure

Primary outcomes

  1. radioactivity measured to determine pharmacokinetics of 124I-hu3F8

    Following 124I-hu3F8 administration, upon completion of normal saline flush, blood will be drawn for pharmacokinetic studies at the following time points: 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120-144 h.after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.

    Time frame: 2 years

Secondary outcomes

  1. PET/CT scan images will be analyzed to determine bio distribution of 124I-hu3F8

    124I-hu3F8 will be injected IV followed by PET/CT scans at serial timepoints PET/CT scan images will be analyzed to determine biodistribution of 124I-hu3F8

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2014 (actual). Primary completion is estimated for Nov 2026, 144 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 144 months is above that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Dec 4, 2014
StartActual
Nov 2014
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02307630
Collaborators
Y-mAbs Therapeutics
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Nov 2014
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 4, 2025

Study contacts

Shakeel Modak, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion